9mhv
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Monkey TLR7 ectodomain with small molecule agonist 9== | |
| + | <StructureSection load='9mhv' size='340' side='right'caption='[[9mhv]], [[Resolution|resolution]] 2.45Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[9mhv]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Macaca_mulatta Macaca mulatta]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=9MHV OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=9MHV FirstGlance]. <br> | ||
| + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.45Å</td></tr> | ||
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=A1BLT:(3~{S})-3-[[2-azanyl-5-[[2-methoxy-5-[[[(3~{S})-oxolan-3-yl]amino]methyl]phenyl]methyl]pyrimido[5,4-b]indol-4-yl]amino]hexan-1-ol'>A1BLT</scene>, <scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=CIT:CITRIC+ACID'>CIT</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=9mhv FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=9mhv OCA], [https://pdbe.org/9mhv PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=9mhv RCSB], [https://www.ebi.ac.uk/pdbsum/9mhv PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=9mhv ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | == Function == | ||
| + | [https://www.uniprot.org/uniprot/B3Y653_MACMU B3Y653_MACMU] | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Dual activation of the TLR7 and TLR8 pathways leads to the production of type I interferon and proinflammatory cytokines, resulting in efficient antigen presentation by dendritic cells to promote T-cell priming and antitumor immunity. We developed a novel series of TLR7/8 dual agonists with varying ratios of TLR7 and TLR8 activity for use as payloads for an antibody-drug conjugate approach. The agonist-induced production of several cytokines in human whole blood confirmed their functional activity. Structure-activity relationship studies guided by structure-based drug design are described. | ||
| - | + | Structure-Based Design of Novel TLR7/8 Agonist Payloads Enabling an Immunomodulatory Conjugate Approach.,Poudel YB, Lo JC, Norris DJ, Cox M, He L, Johnson WL, A M Subbaiah M, Mondal S, Thangavel S, Subramani L, Reddy M, Jain S, Weiss DR, Sivaprakasam P, Critton D, Mulligan D, Xie C, Dhar P, Li Y, Sega E, Yamazoe S, Gavai AV, Mathur A, Zapf CW, Chekler EP ACS Med Chem Lett. 2024 Dec 19;16(1):80-88. doi: 10.1021/acsmedchemlett.4c00463. , eCollection 2025 Jan 9. PMID:39811121<ref>PMID:39811121</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | [[Category: | + | </div> |
| + | <div class="pdbe-citations 9mhv" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Macaca mulatta]] | ||
| + | [[Category: Critton DA]] | ||
Current revision
Monkey TLR7 ectodomain with small molecule agonist 9
| |||||||||||
